Artiva Biotherapeutics, Common Stock Net Income

ARTV Stock   6.53  0.25  3.69%   
Artiva Biotherapeutics, Common fundamentals help investors to digest information that contributes to Artiva Biotherapeutics,'s financial success or failures. It also enables traders to predict the movement of Artiva Stock. The fundamental analysis module provides a way to measure Artiva Biotherapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Artiva Biotherapeutics, stock.
Last ReportedProjected for Next Year
Net Loss-24.9 M-26.2 M
Net Loss-25.8 M-27.1 M
Net Loss(3.40)(3.58)
Net Income Per E B T 0.90  0.80 
Net Loss is likely to drop to about (26.2 M) in 2025. Net Loss is likely to drop to about (27.1 M) in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Artiva Biotherapeutics, Common Company Net Income Analysis

Artiva Biotherapeutics,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Artiva Biotherapeutics, Net Income

    
  (28.72 M)  
Most of Artiva Biotherapeutics,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artiva Biotherapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Artiva Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Artiva Biotherapeutics, is extremely important. It helps to project a fair market value of Artiva Stock properly, considering its historical fundamentals such as Net Income. Since Artiva Biotherapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artiva Biotherapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artiva Biotherapeutics,'s interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Artiva Biotherapeutics, Common reported net income of (28.72 Million). This is 108.42% lower than that of the Biotechnology sector and 141.0% lower than that of the Health Care industry. The net income for all United States stocks is 105.03% higher than that of the company.

Artiva Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artiva Biotherapeutics,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artiva Biotherapeutics, could also be used in its relative valuation, which is a method of valuing Artiva Biotherapeutics, by comparing valuation metrics of similar companies.
Artiva Biotherapeutics, is currently under evaluation in net income category among its peers.

Artiva Fundamentals

About Artiva Biotherapeutics, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Artiva Biotherapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artiva Biotherapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artiva Biotherapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.